Ulnar Nerve Ligation After Removal of Norplant: a Case Report. by Adkinson, Joshua M, MD & Talsania, Jay S, MD
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Surgery
Ulnar Nerve Ligation After Removal of Norplant: a
Case Report.
Joshua M. Adkinson MD
Lehigh Valley Health Network
Jay S. Talsania MD
Lehigh Valley Health Network, jay.talsania@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/surgery
Part of the Other Medical Specialties Commons, and the Surgery Commons
This Article is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Adkinson, J. M., & Talsania, J. S. (2013). Ulnar nerve ligation after removal of Norplant: a case report. Hand (New York, N.Y.), 8(1),
92-96. doi:10.1007/s11552-012-9454-9
CASE REPORTS
Ulnar nerve ligation after removal of Norplant: a case report
Joshua M. Adkinson & Jay S. Talsania
Published online: 12 October 2012
# American Association for Hand Surgery 2012
Introduction
Levonorgestrel implants are an acceptable and effective
long-term option for reversible contraception [6, 11]. These
synthetic, biologically active progestogen products have
been available since 1975 [7] and have undergone many
formulation changes. The Norplant system consists of six
2.4×34 mm silicone tubes [6], while newer preparations,
such as Implanon, contain only a single rigid capsule [20,
23] and are preloaded for ease of insertion [21]. Norplant
has since been discontinued and replaced, however, because
of the unavailability of one of its components [36].
As suggested by the manufacturer, Wyeth-Ayerst Labo-
ratories, [6, 30, 44], Norplant capsules are placed subder-
mally along the medial aspect of the nondominant arm.
Through a 2-mm incision, the implants are distributed in a
fanlike pattern 6–10 cm proximal to the elbow. Often, the
procedure takes less than 10–15 min [44]. The removal
procedure generally takes twice as long [21] and involves
a 4-mm incision made at the apex of the insertion site, using
forceps for extraction of the capsule(s) [30, 44].
While there is evidence of the efficacy and safety of
implantable contraceptives [6, 44], both insertion and re-
moval procedures for these implants have been associated
with complications. Insertion site complications were noted
in 5.9 % of women within the first year of use [15]. Re-
moval complications were reported in 4.5 % of women,
most commonly from implant breakage or embedment in
the subdermal plane [10]. Further, 48 % of women experi-
enced significant pain during implant removal [12]. We
describe a case of significant neuropathy after ulnar nerve
ligation during the removal of a Norplant implantable
contraceptive.
Case Report
A 38-year-old right hand-dominant female presented for
evaluation of numbness and tingling of the left ring and
small finger. The patient stated that the symptoms began
after a Norplant implantable contraceptive device was re-
moved from her upper arm 3 weeks prior to evaluation. Her
implant had been in place for 5 years without complication
and had been functioning appropriately. At the time of
removal, she noted severe pain radiating distally towards
the elbow and into the fingers. In the interim, she also noted
increasing difficulty using the left hand secondary to clum-
siness, numbness, and tingling. Her past medical history
was otherwise unremarkable. The details of the insertion
and removal procedures were unavailable for review.
Physical exam showed good range of motion of her neck
with limited motion of her left shoulder secondary to guard-
ed positioning of the left arm. Visual inspection revealed a
wound 7 cm proximal to the left medial epicondyle, with an
exposed braided suture (Fig. 1). A marked Tinel’s sign was
present at the site of the exposed suture and throughout the
distribution of the ulnar nerve. The hand was edematous
with decreased active range of motion and inability to ab-
duct the digits. She was unable to flex the ring and small
fingers and could not cross her fingers (Fig. 2). A Warten-
berg’s and Froment’s sign (Fig. 3) were evident, as was an
early claw deformity. Semmes–Weinstein was noted at 6.65
in the small finger and 4.31 in the ulnar nerve distribution of
the ring finger. Static two-point discrimination was >15 mm
along the small finger and 11 mm in the ulnar nerve
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distribution of the ring finger. Tip pinch was 16 lb per
square inch (PSI) on the right and 1 PSI on the left. Jamar
grip strength dynamometry in the second position was
55 PSI on the right and 3 PSI on the left.
X-ray studies were obtained of the upper arm and elbow
and these were unremarkable. Electromyography and nerve
conduction tests were notable for an ulnar nerve conduction
velocity of 12.93 m/s (nml, >50 m/s) and amplitude of
0.38 mV (nml, >5.0 mV) between the midhumerus and the
elbow consistent with severe axonal compromise. Contra-
lateral midhumerus to elbow ulnar nerve conduction veloc-
ity was found to be >50 m/s with an amplitude of >5.0 mV.
Distal sensory latency for the ulnar nerve was absent. She
had 3+ sharp waves and denervation changes in the left first
dorsal interosseous, left abductor digiti minimi, and left
flexor carpi ulnaris muscles. The median nerve latencies
and amplitudes were within normal parameters.
Due to the concern for ulnar nerve injury, the patient was
taken to the operating room for exploration. The previous
surgical incision was incised longitudinally for 5 cm. Within
the wound, a large braided suture was noted and, upon further
exploration, was found to be completely encircling the ulnar
nerve (Fig. 4). A 25% area of focal constriction was also found.
The suture was removed and neurolysis was performed prox-
imally and distally. Due to poor perfusion of the nerve upon
release of the tourniquet, epineurotomy was performed under
loupe magnification with subsequent improvement of nerve
perfusion (Fig. 5). The wounds were then closed uneventfully.
Follow-up was performed at 1, 2, 6, 8, 12, 20 weeks and
1 year. At 2 weeks, her paresthesias were improving, the
sutures were removed, and she began hand therapy. At
6 weeks, her elbow and wrist motion had improved dramat-
ically. Her intrinsic function had minimal improvement by
8 weeks. Repeat electrodiagnostic studies showed an
Fig. 1 Preoperative photograph of the left upper arm wound with an
exposed braided suture (black arrow)
Fig. 2 Preoperative photograph showing inability to cross fingers
Fig. 3 Preoperative photograph showing Froment’s sign
Fig. 4 Intraoperative photograph showing point of constriction (black
arrow) and suture completely encircling the ulnar nerve (white arrow)
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increased ulnar nerve conduction velocity of 37.74 m/s
across the zone of injury. A markedly increased motor
amplitude (3.41 mV), indicating significant increase in the
number of functioning motor axons, was also found. By
20 weeks, her intrinsic function had improved and less
clawing was evident. Semmes–Weinstein was noted at
4.31 in the small finger and 3.61 in the ulnar nerve
distribution of the ring finger. At 1 year follow-up,
Jamar grip strength dynamometry in the second position
was 90 PSI on the right and 55 PSI on the left. Despite
these gains, she continued to have persistent first dorsal
interosseous muscle wasting.
Discussion
Neuropathy related to implantable contraceptive devices is
an unusual, yet potentially significant, situation and has
been described previously [37]. Wechtelsberger et al. noted
injury to the medial antebrachial cutaneous nerve during
both implantation and removal of an Implanon device
[43]. Gillies et al. noted two cases of significant median
nerve injury following dissection of the arm during removal
[13]. Others describe injuries to the musculocutaneous nerve
[20] or transient post-operative paresthesias of the ulnar nerve
[42]. Osman et al. and Allouch et al. report cases of iatrogenic
lesions of the ulnar nerve after insertion of a contraceptive
implant [1, 25], while Smith et al. describe a case of prolonged
intrinsic muscle weakness after removal of the implant [37].
These risks increase dramatically if the implant is inserted
deeply or around the brachial groove where multiple major
neurovascular structures are located [32].
When removal is found to be difficult, additional modal-
ities are available to assist with a safe, successful extraction
[2–6, 8, 14, 16, 18, 24, 27, 29, 31, 33–35, 38–41, 45].
Multiple authors describe techniques whereby ultrasound
guidance can be utilized to assist with implant removal [1,
2, 5, 8, 13, 39]. Such implants can be localized with a 10–
14 MHz transducer [11] or, when necessary, magnetic reso-
nance imaging [23]. Use of X-ray and computerized tomog-
raphy has become obsolete, however, as the currently
available implants are not radio opaque [11]. Lastly, Osman
recommends removal of a nonpalpable implant or an im-
plant associated with neurological symptoms be done by a
trained microsurgeon [25].
Though some removal procedures may be more challeng-
ing and require adjunctive maneuvers, nerve-related sequel-
ae typically resolve without surgical intervention. This is,
however, the first report of ulnar nerve ligation during the
removal procedure and only the second report of surgical
intervention for lack of symptom improvement.
A similar case was described by Marin et al. in 1998 [20].
In their report, a 27-year-old female presented with ulnar
neuropathy where, upon exploration, the nerve was found to
be encased in connective tissue scar. This patient presented
with an axonal losing motor and sensory neuropathy after
removal of Norplant. Despite surgical intervention, she de-
veloped denervation potentials, paralysis of the intrinsic
muscles, and a claw hand. The authors concluded that
“insertion-site complications are not due to Norplant capsu-
les, but rather because of poor surgical technique on the part
of the inserting or removing provider”.
More recently, as newer implantable contraceptives have
been developed, complication rates have decreased [9, 17,
21, 26] and removal times have shortened [22, 26, 28]
owing to the single-tube, semi-rigid design [21], and stan-
dardization of techniques. A simple “pop-out” method using
a 2-mm incision is commonly employed and has been
described previously [21]. Alternatively, some surgeons
prefer to grasp the contraceptive with a hemostat after mak-
ing a small stab incision overlying the palpable implant [19].
Both of these techniques limit unnecessary dissection
around critical structures, thereby mitigating risk of injury.
The contemporary physician has a multitude of surgical
techniques to assist with a difficult removal [3, 16, 20, 24,
27, 29, 31, 34, 35, 38] and providers are now required to
complete a 3-hour Food and Drug Administration-mandated
training session prior to performing implant insertions [11].
However, when neurological symptoms persist after remov-
al, we recommend a repeat nerve conduction study at
4–6 weeks, as the vast majority of symptoms are self-
limited. With lack of improvement, surgical exploration
may be warranted.
An extensive literature search and review of manufactur-
er instructions for use did not yield evidence for or against
placement of these implants into the medial upper arm.
While placement of contraceptive implants into the medial
thigh has previously been suggested for women with a
Fig. 5 Intraoperative photograph of the ulnar nerve after removal of
suture and epineurolysis
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paucity of upper extremity subcutaneous tissue [25], it may
be considered for all women in the future to prevent such
significant complications. Insertion would otherwise be sim-
ilar and major structures are very easily avoided with limited
knowledge of local anatomy. An additional, albeit second-
ary, reason for implantation into the medial thigh would be
the lack of an easily visible insertion and removal site scar.
Conclusion
Mandatory training, increasing experience, and the availabil-
ity of safer products will undoubtedly decrease the risk of
insertion- and removal-associated complications. When pain
or minor neurological symptoms persist, a repeat nerve con-
duction study is warranted at 4–6 weeks. In the rare situation
when a patient experiences significant nerve-related symp-
toms, such as those described in this report, surgical interven-
tion may be required. As with any nerve repair, however, the
multifactorial risks of incomplete return of sensibility and
muscle function exist. Further, it may be prudent to consider
placement of all contraceptive implants into the medial thigh,
to minimize risk for injury to major neurovascular structures.
Implantable contraceptives are, by and large, safe, well-
tolerated, effective, and cost efficient [43], but their risks can
be significant and should be discussed with patients prior to
insertion and removal.
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